Dr. Angela Weyand is a pediatric hematologist oncology and Associate Professor of Pediatrics. She is co-director of a multidisciplinary clinic caring for women, girls and people with the potential to menstruate with bleeding, thrombotic, or hematologic disorders and associate director of the Hemophilia Treatment Center. Her clinical interests are in iron deficiency, Von Willebrand disease, anti-phospholipid antibody syndrome, and hormone provoked thrombosis. She is actively involved in national and international organizations. She is a member of the American Society of Hematology Health Equity Task Force, a co-chair of the International Society for Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee on Women's Health, and a member of the ISTH guidance and guidelines committee.

Dr. Weyand's research interests share substantial overlap with her clinical interests. She has active ongoing projects focused on anti-phospholipid antibody syndrome, Von Willebrand Disease, heavy menstrual bleeding, hormone provoked thrombosis, and iron deficiency. She is passionate about the re-evaluation of reference ranges in hematology which perpetuate health inequity. She is a principal investigator on a national observational study of Von Willebrand Disease through the American Thrombosis and Hemostasis Network. In addition to her own projects, she is involved in multiple collaborative studies and serves as the principal investigator for multiple industry sponsored clinical trials.